Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RARA | P10276 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809982 | 0.78 | HIF1A (0.41) | RXRARARARXRG | |
| SCHEMBL86805 | 0.78 | MAOB (0.62) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL8312185 | 0.77 | RXRA (0.32) | RXRARARARXRG | |
| SCHEMBL8312187 | 0.77 | RXRA (0.32) | RXRARARARXRG | |
| SCHEMBL15362735 | 0.76 | RXRA (0.36) | MAOBMAOARXRARARARXRG | |
| SCHEMBL8308676 | 0.73 | ALDH1A1 (0.54) | MAOBNPC1ALDH1A1HPGDRAB9A | |
| SCHEMBL6913758 | 0.73 | MAOA (0.42) | MAOBMAOARXRARARARXRG | |
| SCHEMBL8312128 | 0.73 | — | — | |
| SCHEMBL8312125 | 0.73 | — | — | |
| SCHEMBL30558386 | 0.73 | MAOB (0.53) | MAOBMAOAGRM5NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2345409-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | Kagoshima University (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-2345409-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | Kagoshima University (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| WO-2010032582-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | 国立大学法人鹿児島大学 (JP) | 2010-03-25 | — | — | WO | disclosed |
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | CBR3, CD47, ATL3 | MAOB 4751/4885MAOA 4792/4885GRM5 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.